In addition, the cytoplasmic localization and tumor-restricted overexpression of SNHG5 make it an attractive candidate for lncRNA-directed therapeutics, building on preclinical experience with antisense oligonucleotides against other oncogenic lncRNAs such as MALAT1 [65,66]. Here, SNHG5 is linked to neoplasm.